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The  acute  toxicity,  cytotoxicity,  genotoxicity  and  antigenotoxic  effects  of  BC were  studied.  Cytotoxicity
of  BC  was  evaluated  in cultured  C3A  hepatoma  cells (HepG2/C3A)  using  a lactate  dehydrogenase  (LDH)
activity  assay.  Acute  toxicity  was  tested  in adults  Wistar  rats  treated  with  a  single  dose  of BC.  The  geno-
toxicity  of  BC  was  evaluated  in vivo  by  the  micronucleus  assay.  BC (0.33–170  g/mL)  added  to  C3A  cell
culture  medium  caused  no  elevation  in  LDH  release  over  the  background  level  recorded  in  untreated
cell  wells.  The  treatment  with  the BC in a single  oral  dose  (2000  mg/kg  body  weight)  caused  no  deaths  or





22.7%)  and increased  the  ratio  of PCE/NCE  (female:  46.10%;  male:  35.25%).  There  was  no alteration  in  the
LDH  release  in the  wells  where  C3A cells  were  treated  with  increasing  concentrations  of  BC  compared  to
the wells  where  the  cells  received  the cell  culture  medium  only  (background  of approximately  20%  cell
death),  indicated  that in  the  dose range  tested  BC  was  not  cytotoxic.  BC was  not  cytotoxic,  genotoxic  or
acutely  toxic.  BC  attenuated  CP-induced  genotoxic  and  myelotoxic  effects.. Introduction
Bacterial Cellulose (BC) is an exopolysaccharide obtained from
ugar cane molasses by ﬂotation in the form of a gelatinous matrix
Paterson-Beedle, Kennedy, Melo, Lloyd, & Medeiros, 2000). It is
omposed of stable polymerized sugars. Owing to its chemical
omposition and physical properties, BC is a promising biomate-
ial for many medical and biological uses (Coelho et al., 2002; Lee,
uldum, Mantalaris, & Bismarck, 2014; Martins, Lima, Araujo, Vilar,
 Cavalcante, 2013; Silva, Aguiar, Marques, Coelho, & Rolim Filho,
006; Teixeira, Pereira, Ferreira, Miranda, & Aguiar, 2014). It has
een used in different areas of surgery, such as urethral reconstruc-
ion (Chagas, Aguiar, Vilar, & Lima, 2005), bio-sling for treatment of
rinary incontinence (Gonc¸ alves et al., 2006; Lucena et al., 2005),
nd as a bulking agent in orthopedics (Albuquerque, Santos, Aguiar,
ontes, & Melo, 2011), ophthalmology (Cordeiro-Barbosa, Aguiar,
ira, Pontes Filho, & Bernardino-Araújo, 2012) and urology (Lima
t al., 2015).
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razil.
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Although offering no foreseeable risks to patients, an exper-
imental assessment of the cytotoxic and genotoxic potential of
BC remains necessary to ensure that it is safe for use in medical
products.
The present study was undertaken to evaluate BC cytotoxicity on
the human cell line (HepG2/C3A) and its in vivo genotoxic potential.
A possible modulation of cyclophosphamide (CP)-caused genotoxic
and myelotoxic effects by BC was also investigated using the mouse
bone marrow micronucleus test.
2. Materials and methods
2.1. Test material: Bacterial Cellulose (BC)
BC was produced from sugar cane at the Carpina Experimen-
tal Station of the Federal Rural University of Pernambuco, Brazil
(Paterson-Beedle et al., 2000). Sugar cane molasses is the only raw
material used for the synthesis of BC. The molasses is adjusted
to the ideal brix in order to facilitate the digestion process. Once
synthesized, the biopolymer is submitted to a chemical procedure
to reduce residual sugars. It is then converted to a gel by a frag-
mentation technique and by mechanical shock. At this preparation
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hat produces the BC matrix. From the BC matrix, three products
re obtained: a ﬁlm, a hydrogel and lyophilized forms of the BC.
BC samples tested in this study were prepared from 0.8%
ydrogel.
Preparations of BC acquire viscoelastic properties and remain
table at concentrations of 0.6% and 0.8% at the usual storage
emperatures and in biological ﬂuids (0–40 ◦C). These properties
ake it applicable in vivo (Pita et al., 2015). Owing to its chemical
omposition and physical properties, BC does not induce immune
esponses and thus it is regarded as a promising biomaterial with an
xtensive range of applications in biological and medical sciences
Lee et al., 2014).
.2. Cytotoxicity assay
.2.1. Cell culture conditions
C3A hepatoma cells [HepG2/C3A, derivative of HepG2 (ATCC
B-8065)] (ATCC® CRL-10741TM) were maintained in 75 cm2 cul-
ure ﬂasks in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Sigma
6046) supplemented with 2 mM l-glutamine, 10% fetal bovine
erum (FBS) and 100 U/mL penicillin/100 g/mL streptomycin at
7 ◦C in a 5% CO2 atmosphere (Küblbeck et al., 2011). The cells were
ubcultured once a week and cells used in this study were from
assages 15 and 16. Cell viability was evaluated at each subculture
sing a 0.4% trypan blue solution.
.2.2. Treatment of C3A cells
BC was dissolved in the culture medium and solutions were
repared to reach the following target concentrations in the
ells (in replicates of 4 wells for each BC concentration tested):
70 g/mL, 85 g/mL, 42.5 g/mL, 21.25 g/mL, 10.625 g/mL,
.3 g/mL, 2.65 g/mL, 1.328 g/mL, 0.66 g/L and 0.33 g/mL.
C3A cells were plated on 48-well culture plate wells (5.3 × 104
ells/cm2). The cells were treated with BC solutions and incu-
ated at 37 ◦C in a 5% CO2 incubator for 20 h. Negative controls
eceived an equivalent volume of culture medium in place of BC
olution.
.2.3. Measurement of lactate dehydrogenase (LDH) activity
At the end of the incubation period, BC cytotoxicity was  evalu-
ted by measuring lactate dehydrogenase (LDH) activity (CytoTox
6® Non-Radioactive Cytotoxicity Assay kit; Promega G1780)
ccording to manufacturers’ instructions. Brieﬂy, 50 L cell-culture
edium from each well from the 48-well plate was collected and
ransferred to the wells in a 96-well plate. The 48-well plate was
ubmitted to a freeze–thaw cycle and afterwards 50 L of the cell
ulture medium was collected and transferred to wells in the 96-
ell plate. The reconstituted substrate mix  (50 L) was  added to
ll wells and let stand, protected from light at room tempera-
ure for 30 min. 50 L of the Stop solution was added to each
ell and the plate was taken to read the absorbance at 490 nm in
 microplate spectrophotometer reader Spectramax Plus – Molec-
lar Devices®, with 4.0 SoftmaxPro software for Macintosh® and
indows®. Background values (cell culture medium) were sub-
racted from the sample readings for phenol red correction. An LDH
ositive control (bovine heart LDH) supplied with the kit was used
o validate the assay. Percentages (%) of cell death (percentage of
DH release) were determined using the formula: (experimental
DH release/maximum LDH release) × 100.
.3. Acute toxicity test.3.1. Animals
Adult Wistar rats, 5 males and 5 females, approximately 85
ays old, were used in the experiment. The animals were indi-
idually housed in rat standard plastic cages with stainless steellymers 137 (2016) 556–560 557
coverlids and wood shavings, under controlled environmental con-
ditions (light–dark cycle of 12 h; temperature 22 ± 1 ◦C; relative
humidity approximately, 70%). A standard rodent pellet diet (Nuvi-
tal, Nuvilab Ltd., Curitiba, PR, Brazil) and water were provided
ad libitum.
2.3.2. Treatment
The animals received a single dose of BC (2.000 mg of BC to
0.8%/kg of body weight, bw) by gavage. The maximum (limit)
dose was  chosen based on OECD 423 protocol recommenda-
tions (OECD, 2001). Since this upper limit dose caused no deaths
and any discernible signs of toxicity, lower doses were not
tested.
The animals were weighed daily and BC was administered after
a 12-h fasting period.
2.3.3. Signs of toxicity
Rats were examined for behavioral changes or any clinical sign
of toxicity every 30 min  during the ﬁrst 4 h following the treatment
and thereafter once a day for 14 consecutive days. The animals were
euthanized with a lethal dose of sodium thiopental, administered
intraperitoneally. After euthanasia, all animals were submitted
to necropsy and organs were macroscopically inspected for any
abnormality.
The procedures were performed at the Center for Experimental
Surgery/UFPE, Recife, PE, Brazil.
2.4. In vivo mouse bone marrow micronucleus assay
2.4.1. Animals
Adult Swiss Webster (Mus musculus) mice (25 males and 25
females), approximately 55 day-old, from the Fiocruz Central Ani-
mal  House breeding stock, were used in the experiments. The
animals were housed individually in standard mouse plastic cages
with stainless steel coverlids, and kept under controlled environ-
mental conditions (light–dark cycle of 12 h; room temperature
22 ± 1 ◦C; relative humidity approximately, 70%). A standard rodent
pellet diet (Nuvital, Nuvilab Ltd., Curitiba, PR, Brazil) and ﬁltered
water were provided ad libitum.  This study was performed in accor-
dance with International Agency recommendations (FDA, 2000;
OECD, 2013).
2.4.2. Treatment
For this study, animals were divided into six groups, each group
consisting of 5 male and 5 female mice. Groups were one vehicle
(water) control group, one positive control group (cyclophos-
phamide, CP), two BC-treated groups and an additional group of
mice that received BC orally for 3 days and a single dose of CP by
the ip route on the third day (group 6).
Vehicle controls received water orally (po) at a dose of 10 mL/kg
bw/d (group 1). BC-treated groups were administered with a dose
as high as 200 mg  BC 0.8%/kg bw/d for 3 consecutives days admin-
istered by gavage (group 2) or by intraperitoneal injection (group
3). Positive control mice (group 4) were treated intraperitoneally
(ip) with a single dose of cyclophosphamide (CP, 25 mg/kg bw ip).
To evaluate whether BC would alter CP-induced clastogenic effects,
animals were treated (group 5) by gavage (po) with BC (200 mg  BC
to 0.8%/kg bw/day) for 3 consecutive days and with CP (25 mg/kg
bw ip) 45 min  after the third dose of BC.
Animals were observed once a day for clinical signs of toxicity.
Mouse body weights were recorded on treatment days. Twenty-
four hours after CP injection or the last dose of BC or the vehicle, all
animals were euthanized. The bone marrow was  ﬂushed from both
femur bones with an injection of fetal calf serum to obtain bone
marrow cell suspensions.
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.4.3. Preparation of bone marrow cell slides, analysis and data
nterpretation
The air-dried slides of bone marrow cell suspensions were
tained with May-Grunwald and Giemsa for evaluation (Krishna
 Hayashi, 2000). Slides were scored under a light microscope
magniﬁcation 100× with an immersion objective) by an expe-
ienced evaluator kept unaware of mouse prior treatment. To
etermine the ratio of PCE to total erythrocytes (PCE + NCE), at least
00 erythrocytes (i.e., polychromatic erythrocytes (PCE) plus nor-
ochromatic erythrocytes (NCE)) from each animal were scored
CE/NCE = [(PCE/(PCE + NCE) − PCE)]. The increase of the PCE (%) in
he group 5 was calculated by the formula: [(PCE/NCE in group
) − (PCE/NCE in group 4)]. To calculate the incidence of micronu-
leated polychromatic erythrocytes (MNPCE) a minimum of 2000
CEs were scored per mouse. The percentage of reduction of
P-caused increase in MNPCE was calculated using the formula
s follows (Waters, Brady, Stack, & Brockman, 1990): Reduc-
ion of CP-genotoxicity (%) = [(MNPCE in CP-treated) − (MNPCE
n BC + CP)/(MNPCE in CP − MNPCE in vehicle control)] × 100. All
xperiments were performed at the Laboratory of Environmental
oxicology, National School of Public Health, Oswaldo Cruz Foun-
ation, Rio de Janeiro, RJ, Brazil.
.5. Ethical clearance for animal experimentation
The study protocol was approved by the Ethics Committee for
nimal Care of the Oswaldo Cruz Foundation, FIOCRUZ (CEUA-
IOCRUZ, Protocol No. P-19/14-4; License No. LW-3/15).
.6. Statistical analysis
Data were analyzed by one-way analysis of variance (ANOVA)
r, alternatively, by the Kruskal–Wallis test whenever the data
id not ﬁt a normal distribution. Differences between two groups
ere tested by two-tailed Student’s t-test, Tukey test post hoc test,
r Mann–Whitney U-test. Proportions were evaluated by the chi-
quare test or, alternatively, by the Fisher exact test. Statistical
nalysis was performed using the GraphPad Prism 5.0 program
GraphPad Software Inc., USA), and a difference was  considered
tatistically signiﬁcant at p < 0.05.
. Results
.1. Cytotoxicity – LDH release
Cytotoxicity was assessed by measuring LDH in the medium
fter 20 h cell treatment with different concentrations of BC. Results
LDH release expressed as % of maximum LDH obtained for total
ell lysis) presented here are the mean of two independent exper-
ments. Statistical analysis (ANOVA) showed that there was no
lteration in the LDH release in the wells where C3A cells were
reated with increasing concentrations of BC (0.33–170 g/mL)
ompared to the wells where the cells received the cell culture
edium only (background of approximately 20% cell death) (Fig. 1).
hese results indicated that in the BC dose range tested, the BC was
ot cytotoxic.
.2. Acute toxicity test
No deaths or any other clinical signs of toxicity were noted
n rats treated with BC. All BC-treated rats (2000 mg/kg bw po)
ncreased their body weight during the 14 post-treatment days.
he mean body wt before treatment was 346.4 ± 41.2 g and after
reatment it was 370.4 ± 38.4 g. No gross pathological abnormality
as observed in major organs at necropsy and so histology wasFig. 1. LDH release (%) in culture medium after a 20 h treatment of C3A cells with
BC (0, 0.33, 0.66, 1.328, 2.65, 5.3, 10.625, 21.25, 42.5 and 170 g/mL).
considered unnecessary. Since no toxicity was noted at this rather
high dose, lower doses were not tested.
3.3. In vivo mouse bone marrow cell micronucleus assay
BC caused no deaths or any clinical signs of toxicity in treated
mice. Three-day treatment with BC (200 mg/kg bw/d × 3d, ip and
po) caused no statistically signiﬁcant changes in mouse mean body
weights (females, p = 0.2977; males, p = 0.1844).
Results of the bone-marrow micronucleus assay are summa-
rized in Table 1. The ratios of MNPCE to PCE in male and female
mice treated with BC (200 mg/kg bw/d × 3d, po, ip) were compara-
ble to those background ratios obtained for vehicle-control animals.
Nonetheless, in the group of mice treated with BC the myelotoxic
(ratio of PCE/NCE) and clastogenic (% of MNPCE) effects of CP were
clearly attenuated.
4. Discussion
Bacterial Cellulose (BC), a by-product of the sugarcane produc-
tion process, has a chemical structure that consists of polymerized
sugars. This biopolymer is stable and is not digested by the sur-
rounding tissues (Paterson-Beedle et al., 2000; Pita et al., 2015).
Although a product of natural origin, BC must undergo a rig-
orous safety assessment to meet national and international safety
testing requirements, before it can be placed on the market in dif-
ferent countries. Product safety assessment involves a number of
tests to disclose any potential health risk under normal conditions
or reasonably foreseeable conditions of use (ANVISA, 2001; FDA,
1994).
In this article we presented and discussed results from a set
of preliminary toxicity tests including an in vitro cytotoxicity test
(LDH release in cultured HepG2 cells) (Küblbeck et al., 2011), an
acute toxicity test (OECD, 2001) and an in vivo genotoxicity assay
(mouse bone marrow micronucleus test) (FDA, 2000; OECD, 2013).
The LDH cytotoxicity assay is based on the release of lactate
dehydrogenase into the culture medium whenever plasma cell
membranes are broken (e.g., cell lysis). In this study, an in vitro stan-
dardized assay was performed to investigate whether BC (0.8%) in
tested in growing concentrations up to 170 g/mL would damage
seeded C3A cells. Negative results obtained in this assay are con-
sistent with those of a previous study, in which in vitro cytotoxicity
of Bacterial Cellulose was evaluated in rat alveolar macrophages
using [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] (MTT) assay, cells adhesion rate and nitric oxide production,
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Table  1
Summary of bone marrow cell micronucleus test results after administration of BC (200 mg/kg bw/d × 3d) by oral (po, gavage) or intraperitoneal route (ip) to male and female
Swiss  Webster mice.
Groups Females Males
MNPCE (%) Inhibition (%) PCE/NCE Increase (%) MNPCE (%) Inhibition (%) PCE/NCE Increase (%)
1. Vehicle-control (po) 0.19 ± 0.09b,e – 1.09 ± 0.09b – 0.10 ± 0.09b,e – 1.12 ± 0.13b,e –
2.  BC (ip) 0.21 ± 0.04b,e – 1.07 ± 0.16b – 0.13 ± 0.04b,e – 1.20 ± 0.26b,e –
3.  BC (po) 0.17 ± 0.04b,e – 1.20 ± 0.16b,e – 0.16 ± 0.06b,e – 1.17 ± 0.07b,e –
4.  CP (25 mg/kg bw,  ip) 1.66 ± 0.15 – 0.38 ± 0.03 – 1.33 ± 0.20 – 0.42 ± 0.12 –
5.  BC (po) + CP (25 mg/kg bw, ip) 0.97 ± 0.07a,b,c,d 46.94 0.84 ± 0.07b 46.10 1.05 ± 0.15a,b,c,d 22.76 0.77 ± 0.09a,b,c,d 35.25
CP: cyclophosphamide (positive control, 2 mg/kg bw, ip); BC: Bacterial Cellulose; po: gavage; ip: intraperitoneal injection; MNPCE: micronucleated polychromatic erythro-
















































e BC po + CP ip.
ice were euthanized 24-h after the last administration of BC, CP or the vehicle. In
here results did not differ from the negative controls (Castro et al.,
004).
The in vivo tests (rat acute toxicity, and mouse bone marrow
icronucleus test) conducted with BC are also recommended by
nternational guidelines (ANVISA, 2001; FDA, 1994, 2000; OECD,
001, 2013).
Acute toxicity tests are intended to evaluate the detrimental
ffects that may  arise from a single or several doses administered
ver a period not exceeding 24 h. Since toxic effects may  occur after
 long latency period, treated animals should be observed for at
east one or two weeks after treatment (ANVISA, 2001; Lucena et al.,
015; Naik, Rozman, & Bhat, 2013). Dose selection is one of the most
ritical issues when designing the study. Choosing an adequate dose
nd avoiding killing unnecessarily a large number of animals should
e a priority goal. In this study we selected 2000 mg/kg because it
s a reasonably high dose for this test. As no sign of toxicity was
ound at this very large dose, we decided against testing lower
oses.
The mouse bone marrow micronucleus (MN) assay is one of the
ost used in in vivo tests for the evaluation of the genotoxic poten-
ial of chemicals. Rodent micronucleus assay is considered to be a
eliable, quick and sensitive screening method for genotoxic car-
inogens (carcinogens which act by causing genetic damage). The
requency of micronuclei in treated cells is a biomarker for chro-
osomal damage and chromosomal losses (clastogenic) (OECD,
013). In the MN  assay, reductions in polychromatic erythrocyte
PCE)/normochromatic erythrocyte (NCE) ratio compared to vehi-
le controls indicate unspeciﬁc toxicity to bone marrow cells or
yelotoxic, thus providing an index of mitotic activity (Naik et al.,
013). In this study, BC caused no alteration of the PCE/NCE ratio,
hile the positive control agent CP dose (25 mg/kg bw ip) produced
 marked reduction of the ratio (in male and female mice) compared
o the vehicle control group ratio. BC also did not alter the incidence
f MNPCE (in males and females), indicating that this biopolymer
as not genotoxic/clastogenic to Swiss Webster mice.
Moreover, BC clearly antagonized the myelotoxic and geno-
oxic effects of CP in the assay. The mode of action (MOA) by
hich BC protects against CP-genotoxicity and myelotoxic, how-
ver, remains unclear. Further research should clarify whether the
C-protective effect is dose-dependent and whether it is observed
ith direct clastogens and also with other indirect clastogens (i.e.,
enotoxic compounds requiring metabolic activation). Possible BC
OAs might involve a blockade of CP-activation by CYPs and/or
ntioxidant effects, and/or other actions.
Data provided by experiments reported in this paper add to
xisting data suggesting that BC is a promising material for a
umber of medical uses. Previous studies have shown that mes-
nchymal stem cells (MSC) adhere to a biopolymer ﬁlm and suggest or inhibition % compared to group 4 (CP = 100%).
that BC ﬁlms could be used as cell culture substrates as a good
platform for cell adhesion (Fragoso et al., 2014). It is known that
BC is biocompatible and a material able to induce tissue remodel-
ing and to integrate physiologically with tissue (Cordeiro-Barbosa
et al., 2012; Fragoso et al., 2014; Lima et al., 2015; Lucena et al.,
2015).
A recent study using biopolymer gel as implant in eviscerated
rabbit eyes indicated that BC is similar to polytetraﬂuoroethylene
(PTFE) and polypropylene (Prolene®) in biocompatibility, and inte-
grates adequately with the surrounding tissues (Cordeiro-Barbosa
et al., 2012).
Likewise, when implanted in the bladder wall, BC is uniformly
integrated and preserves its function as a bulking agent. In the blad-
der wall, BC induces a remodeling process at the site of injection,
fully replacing the normal bladder tissue, and inducing forma-
tion of new tissue and extracellular matrix with new vessels. The
incorporation of BC into tissue has been clearly demonstrated by
neovascularization, starting at the periphery and moving toward
the center of the implant (Lima et al., 2015).
Therefore, BC seems to be a promising biopolymer that com-
petes favorably with other materials due to its low toxicity, low
production costs, biocompatibility and capability of integration
with different living tissues (Fragoso et al., 2014; Lucena et al.,
2015).
5. Conclusions
The results of our work suggest that BC is safe when admin-
istered orally in rats at 2000 mg/kg body weight in a single dose.
Data provided by the lactate dehydrogenase (LDH) activity assay
indicate that BC is not cytotoxic. Our data also suggest that BC
exerts a protective effect against CP-induced myelotoxicity and
genotoxicity.
Further in vivo studies should also be undertaken to evaluate the
effects of repeated doses, considering biochemical and hematologi-
cal parameters and to conﬁrm the antimutagenic and antigenotoxic
action observed in this study. Nevertheless this may  be prema-
ture until completion of the studies concerning the antimutagenic
effects of BC as well as its indication or contraindication as quimio-
protector agent.
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